This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Moderna (MRNA) Starts COVID-19 Vaccine Study in Adolescents
by Zacks Equity Research
Moderna (MRNA) initiates development of its coronavirus vaccine candidate, mRNA-1273, in adolescent patients in a phase II/III study.
Implied Volatility Surging for Moderna (MRNA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.
Bull of the Day: Quidel (QDEL)
by Kevin Cook
COVID and influenza A+B tests have launched sales and profit estimates triple-digits into 2021
Inflation to Pick Up in 2021: Bet on TIPS ETFs
by Sweta Killa
The expectation for an uptick in inflation has led to investors' flocking to Treasury Inflation Protected Securities (TIPS) ETFs.
Emerging Markets Hit Record High: 5 Top-Performing ETFs YTD
by Sweta Killa
While many emerging market ETFs have been performing remarkably well, we highlight five funds that are leading the space from a year-to-date basis.
Pfizer/BioNTech COVID-19 Vaccine Raises New Safety Concerns
by Zacks Equity Research
The Bell's palsy related side-effects are not alarming enough to preclude FDA from granting emergency approval to Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine.
5 Sector ETFs Still At Cheap Prices Amid Peak Market
by Sweta Killa
Though many sectors are hitting new highs amid the peak market, some funds are still down from a year-to-date look and are due to climb in the coming weeks.
Markets Book Profits as Vaccine Rally Stalls; DASH Jumps 86% on IPO
by Mark Vickery
DoorDash (DASH) shares closed its first day on the New York Stock Exchange at $189 per share.
Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Micron Technology, RCI Hospitality, Pfizer, BioNTech and Moderna highlighted as Zacks Bull and Bear of the Day
Equal-Weight ETFs Leading Latest Market Rally: Here's Why
by Sweta Killa
While the rally has been broad-based, equal-weighted ETFs are outperforming their cap-weighted peers.
IPO Market Set to Thrive in December
by Zacks Equity Research
IPO Market Set to Thrive in December
DoorDash IPOs at $102, Vaccine Rally Cooling
by Mark Vickery
DoorDash is pricing its Initial Public Offering at $102 per share, for a valuation of $38.7 billion.
Company News for Dec 9, 2020
by Zacks Equity Research
Companies In The News Are: SFIX,HRB,CMD,MRNA
Pfizer (PFE) Pneumococcal Vaccine BLA Gets FDA's Priority Tag
by Zacks Equity Research
Pfizer's (PFE) 20-valent pneumococcal conjugate vaccine candidate helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia.
Next Chapter in Covid-19 Era Underway
by Mark Vickery
Aside from sub-zero refrigeration requirements, the Pfizer-BioNTech vaccine looks to be first in line and among the highest efficacy rates possible.
Should You Buy Oil & Gas ETFs Now?
by Neena Mishra
Energy ETFs rebounded strongly in November but are still down significantly for the year
Productivity Increases in Q3
by Zacks Equity Research
Productivity Increases in Q3
Moderna (MRNA) to Supply More Doses of COVID-19 Vaccine to Canada
by Zacks Equity Research
Moderna (MRNA) announces deal to supply 20 million additional doses of its COVID-19 vaccine candidate, mRNA-1273, to the Canadian Government, upon potential approval. The total tally is now 40 million doses.
Markets Find Vaccine-Rally Equilibrium; AZO Mixed in Q1
by Mark Vickery
Great Britain injects its first Pfizer (PFE)-BioNTech (BNTX) vaccine patients today, marking a momentous occasion whereby the world may soon return to pre-pandemic activities.
Small-Cap ETFs Face Off: IWM Vs. IJR
by Sweta Killa
Small-cap companies are closely tied to the U.S. economy and are thus poised to outperform when the economy improves.
Pfizer (PFE) Up 14% in 3 Months on COVID-19 Vaccine Progress
by Zacks Equity Research
Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine candidate is now approved for emergency use in United Kingdom and Bahrain.
Markets Close Mixed; Toll Brothers (TOL) Puts Up Record Quarter
by Mark Vickery
It's the hottest home market Toll Brothers has seen in 30 years, with net signed contracts +68% -- an all-time high for any quarter in the company's history.
Can Restaurant Stocks Move Higher?
by Sejuti Banerjea
Restaurant companies have been done a lot of innovating this year and they should do much better next year as pandemic concerns wane.
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Cisco Systems, CVS Health, Moderna, Pfizer and Hilton Worldwide
Markets Hit Record Highs, Promise Further Growth: 5 Top Picks
by Zacks Equity Research
Promising vaccine news and hopes of further fiscal stimulus helped benchmark indexes to close at record highs, making this a prudent time to invest in names like Cabot (CBT) and Forestar (FOR)